Table IV.
Triglycerides | HDL | LDL | |||
---|---|---|---|---|---|
SAT (cm2) | VAT (cm2) | (mg/dL) | (mg/dL) | (mg/dL) | |
Predictor | Effect (se) | Effect (se) | Effect (se) | Effect (se) | Effect (se) |
Age (mos) | .74 (.27)2 | −.04 (.04) | .27 (.38) | −.04 (.05) | −.14 (.14) |
Female | 40 (16)2 | 6.3 (4.0) | −15 (33) | .46 (3.2) | 10 (10) |
White** | 31 (27) | 13 (3.3)4 | 27 (39) | −3.8 (4.4) | −13 (18) |
Hispanic** | 11 (31) | −6 (5.0) | 12 (31) | −10.2 (3.1)4 | −6.3 (12) |
BMI Z score | 52 (8.4)4 | 10 (1.5) 4 | −16.7 (13) | −1.09 (1.8) | 1.3 (4.8) |
Log(VL) | −1.5 (2.5) | .19 (.61) | 2.9 (3.9) | −1.2 (.50)1 | −4.9 (1.7)3 |
PI | 4 (23) | −3.5 (3.5) | 70 (31)1 | −8.9 (3.9) 1 | 15 (7.5) 1 |
NNRTI | −26 (17) | −7.5 (3.0)2 | −20 (28) | 8.2 (2.9) 3 | 4.9 (10) |
NRTI | 49 (27) | 11 (5.6)1 | −23 (41) | 16 (13) | 8.1 (13) |
values in bold represent significant effects.
Compared to Black (reference)
P≤0.05
P≤0.01
P≤0.005
P≤0.001
Log(VL) = log viral load
VAT = visceral adipose tissue
SAT = subcutaneous adipose tissue
BMI = body mass index
PI = protease inhibitor
NRTI = nucleoside reverse transcriptase inhibitor
NNRTI = non- nucleoside reverse transcriptase inhibitor